html[data-identity='g1'] .g1-header .g1-header-wide .g1-header-layers button { display: none; } html[data-identity='g1'] .g1-header-wide .g1-header-layers a { align-self: center; } html[data-identity='g1'] .g1-header .g1-header-narrow { display: none; } html[data-identity='g1'] .g1-header-nojs { display: none; } @media (width < 721px) { html[data-identity='g1'] .g1-header .g1-header-nojs { display: flex; flex-wrap: wrap; column-gap: 20px; padding: 0 16px 8px; } html[data-identity='g1'] .g1-header-nojs ul { display: flex; gap: 20px; list-style: none; margin: 0; padding: 0; box-shadow: none; } html[data-identity='g1'] .g1-header-nojs a { display: block; padding: 6px 0; font-size: 15px; line-height: 24px; color: var(--ink2); text-decoration: none; } html[data-identity='g1'] .g1-header-nojs a[aria-current='true'] { color: var(--ink); text-decoration: underline 2px var(--ember); text-underline-offset: 6px; } }

medium-chain triglyceridesFinding

Medium-chain triglycerides has no detected effect on activities of daily living score

no difference foundVery limited evidenceFinding

01 · The sentence it was drawn from

“Changes in ADL scores were not significantly different between the MCT and placebo interventions (p > 0.05).”

Quoted verbatim from Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4-/-: A double-blind, randomized, placebo-controlled crossover trial.

This finding among the 3 findings on its endpoint

medium-chain triglycerides

Activities of daily living score

no difference found

Who: Adults with mild to moderate Alzheimer's disease, APOE4-/- subjects who completed the study analysed; MCT jelly versus canola-oil placebo jelly in a double-blind crossover
Dose studied: MCT jelly by mouth three times daily, total daily fat dose 17.3 g MCT, 30 days per phase

Very limited evidencePMID 31694759 · 2020

02 · The study

Study: crossover
Duration: 4 weeks

Evidence, by strength

strong
moderate
limited
very limitedthis finding
insufficient

03 · The paper

Clinical nutrition (Edinburgh, Scotland)

Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4-/-: A double-blind, randomized, placebo-controlled crossover trial.

2020PMID 31694759doi 10.1016/j.clnu.2019.10.017

What else it reported1 finding · 0 compounds · 1 endpoint

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M706FVRB9502RNSE6FYT8S2Z